456 related articles for article (PubMed ID: 28552264)
1. Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[
Langen KJ; Stoffels G; Filss C; Heinzel A; Stegmayr C; Lohmann P; Willuweit A; Neumaier B; Mottaghy FM; Galldiks N
Methods; 2017 Nov; 130():124-134. PubMed ID: 28552264
[TBL] [Abstract][Full Text] [Related]
2. O-(2-[18F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results.
Stegmayr C; Willuweit A; Lohmann P; Langen KJ
Curr Radiopharm; 2019; 12(3):201-210. PubMed ID: 30636621
[TBL] [Abstract][Full Text] [Related]
3. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
4. Current trends in the use of O-(2-[
Stegmayr C; Stoffels G; Filß C; Heinzel A; Lohmann P; Willuweit A; Ermert J; Coenen HH; Mottaghy FM; Galldiks N; Langen KJ
Nucl Med Biol; 2021 Jan; 92():78-84. PubMed ID: 32113820
[TBL] [Abstract][Full Text] [Related]
5. Treatment-Related Uptake of
Geisler S; Stegmayr C; Niemitz N; Lohmann P; Rapp M; Stoffels G; Willuweit A; Galldiks N; Filss C; Sabel MC; Coenen HH; Shah NJ; Langen KJ
J Nucl Med; 2019 Oct; 60(10):1373-1379. PubMed ID: 30850492
[TBL] [Abstract][Full Text] [Related]
6. Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic.
Hutterer M; Ebner Y; Riemenschneider MJ; Willuweit A; McCoy M; Egger B; Schröder M; Wendl C; Hellwig D; Grosse J; Menhart K; Proescholdt M; Fritsch B; Urbach H; Stockhammer G; Roelcke U; Galldiks N; Meyer PT; Langen KJ; Hau P; Trinka E
J Nucl Med; 2017 Jan; 58(1):129-137. PubMed ID: 27469356
[TBL] [Abstract][Full Text] [Related]
7. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
Pauleit D; Stoffels G; Bachofner A; Floeth FW; Sabel M; Herzog H; Tellmann L; Jansen P; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
Nucl Med Biol; 2009 Oct; 36(7):779-87. PubMed ID: 19720290
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
9. Update on amino acid PET of brain tumours.
Langen KJ; Galldiks N
Curr Opin Neurol; 2018 Aug; 31(4):354-361. PubMed ID: 29952832
[TBL] [Abstract][Full Text] [Related]
10. Recent Developments of 18F-FET PET in Neuro-oncology.
Muoio B; Giovanella L; Treglia G
Curr Med Chem; 2018; 25(26):3061-3073. PubMed ID: 29173147
[TBL] [Abstract][Full Text] [Related]
11. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas.
Pauleit D; Floeth F; Hamacher K; Riemenschneider MJ; Reifenberger G; Müller HW; Zilles K; Coenen HH; Langen KJ
Brain; 2005 Mar; 128(Pt 3):678-87. PubMed ID: 15689365
[TBL] [Abstract][Full Text] [Related]
12. Relationship of regional cerebral blood flow and kinetic behaviour of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake in cerebral gliomas.
Zhang K; Langen KJ; Neuner I; Stoffels G; Filss C; Galldiks N; Tellmann L; Rota Kops E; Coenen HH; Herzog H; Shah NJ
Nucl Med Commun; 2014 Mar; 35(3):245-51. PubMed ID: 24240195
[TBL] [Abstract][Full Text] [Related]
13. Comparison of O-(2-
Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
World Neurosurg; 2018 May; 113():e727-e737. PubMed ID: 29510293
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of O-(2-[(18)F]-fluoroethyl)-L-tyrosine positron emission tomography in patients with low-grade glioma.
Rapp M; Floeth FW; Felsberg J; Steiger HJ; Sabel M; Langen KJ; Galldiks N
Neurosurg Focus; 2013 Feb; 34(2):E3. PubMed ID: 23373448
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of ¹⁸F labeled FET prodrugs for tumor imaging.
Wang L; Lieberman BP; Ploessl K; Kung HF
Nucl Med Biol; 2014 Jan; 41(1):58-67. PubMed ID: 24183614
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
[TBL] [Abstract][Full Text] [Related]
17. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
18. Applications of positron emission tomography in neuro-oncology: a clinical approach.
Demetriades AK; Almeida AC; Bhangoo RS; Barrington SF
Surgeon; 2014 Jun; 12(3):148-57. PubMed ID: 24629841
[TBL] [Abstract][Full Text] [Related]
19. [Improved diagnostics of cerebral gliomas using FET PET].
Langen KJ; Floeth FW; Stoffels G; Hamacher K; Coenen HH; Pauleit D
Z Med Phys; 2007; 17(4):237-41. PubMed ID: 18254545
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.
Lapa C; Linsenmann T; Monoranu CM; Samnick S; Buck AK; Bluemel C; Czernin J; Kessler AF; Homola GA; Ernestus RI; Löhr M; Herrmann K
J Nucl Med; 2014 Oct; 55(10):1611-6. PubMed ID: 25125481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
